Search Results

A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.

• Authors : Armas D; Celerion Inc., Phoenix, AZ, USA.; Holt RJ

Subjects: Fruit and Vegetable Juices*; Cysteamine/Cysteamine/Cysteamine/*pharmacokinetics ; Cystine Depleting Agents/Cystine Depleting Agents/Cystine Depleting Agents/*pharmacokinetics

• Source: Advances in therapy [Adv Ther] 2018 Feb; Vol. 35 (2), pp. 199-209. Date of Electronic Publication: 2018 Feb 06.Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet

Record details

TRPV1 dysfunction in cystinosis patients harboring the homozygous 57 kb deletion.

• Authors : Buntinx L; Center for Clinical Pharmacology, Department of Pharmaceutical and Pharmacological Sciences, KULeuven, Herestraat 49, 3000 Leuven, Belgium.; Voets T

Subjects: Gene Deletion* ; Homozygote*; Cystinosis/Cystinosis/Cystinosis/*metabolism

• Source: Scientific reports [Sci Rep] 2016 Oct 13; Vol. 6, pp. 35395. Date of Electronic Publication: 2016 Oct 13.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Improvement in the renal prognosis in nephropathic cystinosis.

• Authors : Van Stralen KJ; European Society for Paediatric Nephrology/European Renal Association and European Dialysis and Transplant Association Registry, Department of Medical Informatics, Academic Medical Center, Amsterdam, The Netherlands. ; Emma F

Subjects: Kidney Transplantation*/Kidney Transplantation*/Kidney Transplantation*/adverse effects ; Kidney Transplantation*/Kidney Transplantation*/Kidney Transplantation*/mortality ; Renal Dialysis*/Renal Dialysis*/Renal Dialysis*/adverse effects

• Source: Clinical journal of the American Society of Nephrology : CJASN [Clin J Am Soc Nephrol] 2011 Oct; Vol. 6 (10), pp. 2485-91. Date of Electronic Publication: 2011 Aug 25.Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 101271570 Publication Model: Print-Electronic Cited Medium: Internet

Record details

CTNS mutations in an American-based population of cystinosis patients.

• Authors : Shotelersuk V; Section of Human Biochemical Genetics, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-1830, USA.; Larson D

Subjects: Glycoproteins* ; Point Mutation* ; Sequence Deletion*

• Source: American journal of human genetics [Am J Hum Genet] 1998 Nov; Vol. 63 (5), pp. 1352-62.Publisher: Cell Press Country of Publication: United States NLM ID: 0370475 Publication Model: Print Cited Medium: Print ISSN: 0002-9297 (Print)

Record details

Molecular characterization of CTNS deletions in nephropathic cystinosis: development of a PCR-based detection assay.

• Authors : Forestier L; INSERM U423, Tour Lavoisier 6e étage, Hôpital Necker-Enfants Malades 149, Paris, France.; Jean G

Subjects: Glycoproteins*; Cystinosis/Cystinosis/Cystinosis/*genetics ; Membrane Proteins/Membrane Proteins/Membrane Proteins/*genetics

• Source: American journal of human genetics [Am J Hum Genet] 1999 Aug; Vol. 65 (2), pp. 353-9.Publisher: Cell Press Country of Publication: United States NLM ID: 0370475 Publication Model: Print Cited Medium: Print ISSN: 0002-9297 (Print)

Record details

Cysteamine: new preparation. Chronic treatment of cystinosis.

Subjects: Cysteamine*/Cysteamine*/Cysteamine*/adverse effects ; Cysteamine*/Cysteamine*/Cysteamine*/therapeutic use ; Radiation-Protective Agents*/Radiation-Protective Agents*/Radiation-Protective Agents*/adverse effects

• Source: Prescrire international [Prescrire Int] 1999 Jun; Vol. 8 (41), pp. 67-70.Publisher: Association Mieux Prescrire Country of Publication: France NLM ID: 9439295 Publication Model: Print Cited Medium: Print ISSN:

Record details

Nephropathic Cystinosis Epidemiology Forecast Report 2022: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan, 2019-2032 - ResearchAndMarkets.com.

• Source: Business Wire. 2022.

Record details

Chemical Business NewsBase - EMEA (European Medicines Agency):; Committee for Orphan Medicinal Products public summary of positive opinion for orphan designation of cysteamine; hydrochloride for the treatment of cystinosis.

• Source: Chemical Business NewsBase: EMEA (European Medicines Agency) (United Kingdom), June 29, 2009, 2pp

Record details

Chemical Business NewsBase - EMEA (European Medicines Agency):; Public summary of opinion on orphan designation: Cysteamine bitartrate (gastroresistant) for the treatment of; cystinosis.

• Source: Chemical Business NewsBase (UK), October 18, 2010, 2pp

Record details

Chemical Business NewsBase - Press Release:; Cystinosis Research Foundation awards $1.6 M in grants to find a cure for deadly genetic disease.

• Source: Chemical Business NewsBase (UK), August 6, 2009, 1pp

Record details